Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) FCF Margin (2016 - 2025)

Historic FCF Margin for UroGen Pharma (URGN) over the last 9 years, with Q3 2025 value amounting to 154.13%.

  • UroGen Pharma's FCF Margin fell 439900.0% to 154.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 143.11%, marking a year-over-year decrease of 352600.0%. This contributed to the annual value of 107.37% for FY2024, which is 148000.0% down from last year.
  • UroGen Pharma's FCF Margin amounted to 154.13% in Q3 2025, which was down 439900.0% from 165.05% recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's FCF Margin registered a high of 55.47% during Q4 2023, and its lowest value of 369.91% during Q1 2021.
  • Its 5-year average for FCF Margin is 142.93%, with a median of 145.9% in 2021.
  • In the last 5 years, UroGen Pharma's FCF Margin surged by 63637800bps in 2021 and then tumbled by -559700bps in 2025.
  • Over the past 5 years, UroGen Pharma's FCF Margin (Quarter) stood at 125.34% in 2021, then grew by 4bps to 120.3% in 2022, then surged by 54bps to 55.47% in 2023, then dropped by -1bps to 55.91% in 2024, then tumbled by -176bps to 154.13% in 2025.
  • Its FCF Margin stands at 154.13% for Q3 2025, versus 165.05% for Q2 2025 and 207.7% for Q1 2025.